Hao Lan

Hao Lan

he/him

Enthusiast in Molecular Modelling and Cheminformatics for Drug Discovery

Posts by Tags

AI

Evaluating the Boltz-2 Co-folding Model for Challenging Modalities: A Two-Case Study with Covalent Inhibitor and Macrocyclic Molecular Glue

21 minute read

Published:

Introduction

In the rapidly evolving landscape of drug discovery, Artificial Intelligence (AI) co-folding models have gained significant attention, frequently highlighted in public reports for their potential to revolutionise structure-based drug design (SBDD). These computational tools promise to accelerate the identification and optimisation of novel drug candidates by predicting the intricate interactions and corresponding conformations between receptors and ligands, under induced fit effects. However, despite the widespread enthusiasm, there remains a notable gap in detailed performance investigations, particularly concerning challenging modalities such as covalent inhibitors and the emerging class of molecular glues. For the pharmaceutical industry, where real-world applications demand robust and reliable predictive capabilities, evaluating these models against those complex cases is crucial. This helps us to understand not only what co-folding models can achieve but also their current limitations that need to be improved.

Advanced Molecular Dynamics

Evaluating AI-based Molecular Modelling with Physical Simulation

40 minute read

Published:

Introduction

In my last blog post, I explored Boltz-2 co-folding model applied to novel chemical modalities, including covalent macrocyclic molecular glue Elironrasib and its induced protein complexes. While the post received positive feedback, a detailed investigation was not performed. As both a computational chemist and a growing expert in cheminformatics, I believe it is crucial to analyse current AI models through a physics-based lens, leveraging corresponding data to inspire practical applications within the drug discovery industry.

This new article will serve as a supplement, specifically designed to address two key questions:

1. Which are those 'good' AI models that most closely approach physics as the ground truth, while also maintaining low computational cost?

2. Could physics effectively guide the identification, refinement, or even rescue of 'imperfect' AI models so far for molecular modelling?

Atomic Neural Network Potentials

Evaluating AI-based Molecular Modelling with Physical Simulation

40 minute read

Published:

Introduction

In my last blog post, I explored Boltz-2 co-folding model applied to novel chemical modalities, including covalent macrocyclic molecular glue Elironrasib and its induced protein complexes. While the post received positive feedback, a detailed investigation was not performed. As both a computational chemist and a growing expert in cheminformatics, I believe it is crucial to analyse current AI models through a physics-based lens, leveraging corresponding data to inspire practical applications within the drug discovery industry.

This new article will serve as a supplement, specifically designed to address two key questions:

1. Which are those 'good' AI models that most closely approach physics as the ground truth, while also maintaining low computational cost?

2. Could physics effectively guide the identification, refinement, or even rescue of 'imperfect' AI models so far for molecular modelling?

Statictical and Quantum Mechanics

Evaluating AI-based Molecular Modelling with Physical Simulation

40 minute read

Published:

Introduction

In my last blog post, I explored Boltz-2 co-folding model applied to novel chemical modalities, including covalent macrocyclic molecular glue Elironrasib and its induced protein complexes. While the post received positive feedback, a detailed investigation was not performed. As both a computational chemist and a growing expert in cheminformatics, I believe it is crucial to analyse current AI models through a physics-based lens, leveraging corresponding data to inspire practical applications within the drug discovery industry.

This new article will serve as a supplement, specifically designed to address two key questions:

1. Which are those 'good' AI models that most closely approach physics as the ground truth, while also maintaining low computational cost?

2. Could physics effectively guide the identification, refinement, or even rescue of 'imperfect' AI models so far for molecular modelling?

benchmark

Evaluating the Boltz-2 Co-folding Model for Challenging Modalities: A Two-Case Study with Covalent Inhibitor and Macrocyclic Molecular Glue

21 minute read

Published:

Introduction

In the rapidly evolving landscape of drug discovery, Artificial Intelligence (AI) co-folding models have gained significant attention, frequently highlighted in public reports for their potential to revolutionise structure-based drug design (SBDD). These computational tools promise to accelerate the identification and optimisation of novel drug candidates by predicting the intricate interactions and corresponding conformations between receptors and ligands, under induced fit effects. However, despite the widespread enthusiasm, there remains a notable gap in detailed performance investigations, particularly concerning challenging modalities such as covalent inhibitors and the emerging class of molecular glues. For the pharmaceutical industry, where real-world applications demand robust and reliable predictive capabilities, evaluating these models against those complex cases is crucial. This helps us to understand not only what co-folding models can achieve but also their current limitations that need to be improved.

co-folding

Evaluating the Boltz-2 Co-folding Model for Challenging Modalities: A Two-Case Study with Covalent Inhibitor and Macrocyclic Molecular Glue

21 minute read

Published:

Introduction

In the rapidly evolving landscape of drug discovery, Artificial Intelligence (AI) co-folding models have gained significant attention, frequently highlighted in public reports for their potential to revolutionise structure-based drug design (SBDD). These computational tools promise to accelerate the identification and optimisation of novel drug candidates by predicting the intricate interactions and corresponding conformations between receptors and ligands, under induced fit effects. However, despite the widespread enthusiasm, there remains a notable gap in detailed performance investigations, particularly concerning challenging modalities such as covalent inhibitors and the emerging class of molecular glues. For the pharmaceutical industry, where real-world applications demand robust and reliable predictive capabilities, evaluating these models against those complex cases is crucial. This helps us to understand not only what co-folding models can achieve but also their current limitations that need to be improved.